Wellington Management — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureHercules Capital, Inc.MPM BioImpactVida VenturesForbionRA Capital
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)inMark A. McCamish(Executive Officer, Director)inDavid M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Co-investorsGV (Google Ventures)Nextech InvestVida Ventures
SpotOn is a cloud-based restaurant management system and point-of-sale platform for restaurant operators, offering online ordering, reservations, labor management, and AI-powered financial analysis.
Enterprise SoftwareSaaSSan Francisco, US
Doron Friedman(Founder)inMatthew Hyman(Executive Officer, Director)inZachary Hyman(Executive Officer, Director)inRJ Horsley(Executive Officer)inBryan SolarinMatt Hyman(Founder)
Co-investorsAndreessen HorowitzDragoneer Investment GroupDST Global01 AdvisorsAurumCoatue Management+5 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersCasdin Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.























